Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06776081). This is a study registration, not published results. Lead sponsor: University of Colorado, Boulder. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 84 participants (ESTIMATED). Conditions: Obesity, Weight Loss. Interventions: OTHER: Weight loss without pharmacotherapy. Primary outcome measures: Phase 1: Circulating adipocyte-derived extracellular vesicles (Ad-EVs) , Circulating Ad-EVs will measured during Phase 1 visit 2 which is ~2 weeks from their respective start date.; Phase 2: Circulating adipocyte-derived extracellular vesicles (Ad-EVs) , Circulating Ad-EVs will be measured during Phase 2 visit 15 which is ~17 weeks from their respective start date.; Phase 1: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh) , FBF response to ACh will be measured during Phase 1 and the participant's visit 2 which is ~ 2 weeks from their respective start date.; Phase 2: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh) , FBF response to ACh will be measured during Phase 2 and the participant's visit 15 which is ~17 weeks from their respective start date.; Phase 1: Forearm Blood Flow (FBF) Response to Sodium Nitroprusside (NTP) , FBF response to NTP will be measured during Phase 1 and the participant's visit 2 which is ~ 2 weeks from their respective start date.; Phase 2: Forearm Blood Flow (FBF) Response to Sodium Nitroprusside (NTP) , FBF response to NTP will be measured during Phase 2 and the participant's visit 15 which is ~17 weeks from their respective start date.. Brief summary: Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity. The investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.